Is Co-Diagnostics, Inc. Common Stock (CODX) overvalued?
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on US.
This page asks whether Co-Diagnostics, Inc. Common Stock (CODX) looks expensive on cached numbers — not a short thesis.
Latest reported CODX revenue for 2024-12-31 was $3.9M. Net income was -$37.6M. Revenue was down 42.5% from 2023-12-31 to 2024-12-31. CODX currently screens at market cap $31.4M.
CODX currently screens at market cap $31.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CODX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CODX stock page for the full model, not this heading.
Not investment advice.